89bio Inc (ETNB) - Net Assets
Based on the latest financial reports, 89bio Inc (ETNB) has net assets worth $521.73 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($603.49 Million) and total liabilities ($81.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 89bio Inc (ETNB) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $521.73 Million |
| % of Total Assets | 86.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | 97.47% |
| 10-Year Change | N/A |
| Growth Volatility | 109.36 |
89bio Inc - Net Assets Trend (2018–2024)
This chart illustrates how 89bio Inc's net assets have evolved over time, based on quarterly financial data. Also explore ETNB total asset value for the complete picture of this company's asset base.
Annual Net Assets for 89bio Inc (2018–2024)
The table below shows the annual net assets of 89bio Inc from 2018 to 2024. For live valuation and market cap data, see market value of 89bio Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $400.79 Million | -25.27% |
| 2023-12-31 | $536.31 Million | +253.22% |
| 2022-12-31 | $151.83 Million | +20.54% |
| 2021-12-31 | $125.96 Million | -37.94% |
| 2020-12-31 | $202.96 Million | +125.65% |
| 2019-12-31 | $89.94 Million | +660.15% |
| 2018-12-31 | $-16.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 89bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 80833500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $120.00K | 0.03% |
| Other Comprehensive Income | $563.00K | 0.14% |
| Other Components | $1.22 Billion | 305.55% |
| Total Equity | $400.79 Million | 100.00% |
89bio Inc Competitors by Market Cap
The table below lists competitors of 89bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank of N.T. Butterfield & Son Ltd
NYSE:NTB
|
$2.20 Billion |
|
Alleima AB (publ)
ST:ALLEI
|
$2.21 Billion |
|
Mach Natural Resources LP
NYSE:MNR
|
$2.21 Billion |
|
China-Singapore Suzhou Industrial Park Development Group Co Ltd
SHG:601512
|
$2.21 Billion |
|
Opple Lighting Co Ltd
SHG:603515
|
$2.20 Billion |
|
Quaker Chemical Corporation
NYSE:KWR
|
$2.20 Billion |
|
Autohome Inc
NYSE:ATHM
|
$2.20 Billion |
|
Hilltop Holdings Inc
NYSE:HTH
|
$2.20 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 89bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 536,306,000 to 400,789,000, a change of -135,517,000 (-25.3%).
- Net loss of 367,079,000 reduced equity.
- Share repurchases of 356,000 reduced equity.
- New share issuances of 157,574,000 increased equity.
- Other comprehensive income increased equity by 373,000.
- Other factors increased equity by 73,971,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-367.08 Million | -91.59% |
| Share Repurchases | $356.00K | -0.09% |
| Share Issuances | $157.57 Million | +39.32% |
| Other Comprehensive Income | $373.00K | +0.09% |
| Other Changes | $73.97 Million | +18.46% |
| Total Change | $- | -25.27% |
Book Value vs Market Value Analysis
This analysis compares 89bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-3.50 | $14.84 | x |
| 2019-12-31 | $8.45 | $14.84 | x |
| 2020-12-31 | $12.62 | $14.84 | x |
| 2021-12-31 | $6.27 | $14.84 | x |
| 2022-12-31 | $4.36 | $14.84 | x |
| 2023-12-31 | $7.54 | $14.84 | x |
| 2024-12-31 | $3.83 | $14.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 89bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -91.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-91.59%) is below the historical average (-49.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.57 Million |
| 2019 | -63.84% | 0.00% | 0.00x | 1.06x | $-66.41 Million |
| 2020 | -24.39% | 0.00% | 0.00x | 1.04x | $-69.80 Million |
| 2021 | -71.55% | 0.00% | 0.00x | 1.29x | $-102.72 Million |
| 2022 | -67.20% | 0.00% | 0.00x | 1.30x | $-117.21 Million |
| 2023 | -26.51% | 0.00% | 0.00x | 1.11x | $-195.82 Million |
| 2024 | -91.59% | 0.00% | 0.00x | 1.19x | $-407.16 Million |
Industry Comparison
This section compares 89bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 89bio Inc (ETNB) | $521.73 Million | 0.00% | 0.16x | $2.20 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more